IFNG and neoplasm: As expected, a strong IFNγ response resulted from recognition of the immunodominant epitope of VSV-GP (VSV-NP52–59)39 by the splenocytes of VSV-GP treated mice, which was absent in mock treated or tumour-free naïve mice (Fig. 3c).